Cardiometabolic risk factors in women undergoing the menopausal transition and the potential of drospirenone-containing contraceptive in the correction of the identified abnormalities

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective: To investigate changes in cardiometabolic risk factors in women during menopausal transition and the feasibility of correcting the identified abnormalities using cyclic hormone therapy with drospirenone-containing COC.

Materials and methods: The study enrolled 178 women who underwent a menopausal transition with manifestations of the menopausal syndrome. The study group included 87 women who received COC consisting of drospirenone 3 mg/ethinyl estradiol 20 μg. The control group included 91 women who had not received COC. Kupperman–Uvarova MMI was used to assess the severity of menopausal symptoms. Clinical evaluation included measurements of lipid metabolism, fasting blood glucose, IRI, HOMA-IR, WC, and WC/HC ratio.

Results: More than half of the women had excessive body weight and signs of abdominal obesity, one-third had lipid metabolism disorders, and 41 (23%) were diagnosed with metabolic syndrome. At the end of the study, women in the study group showed a significant reduction in body weight and abdominal obesity. By the end of the study, women in the control group had higher HOMA-IR values, concurrent with higher postprandial blood glucose levels. Women in the study group did not show significant changes in these parameters, and the levels of total and LDL cholesterol were reduced.

Conclusion: The study findings showed a high incidence of metabolic risk factors in women during the menopausal transition. Administration of COC to menopausal women prevents an increase in body weight and visceral obesity, contributes to a decrease in IR and impaired carbohydrate metabolism, and favorably affects lipid metabolism.

全文:

受限制的访问

作者简介

Sergey Tolstov

V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia; Regional Clinical Cardiology Center

编辑信件的主要联系方式.
Email: tolstovsn@mail.ru
ORCID iD: 0000-0002-4546-9449

Dr. Med. Sci., Professor at the Department of Therapy with Courses in Cardiology; Head of the Vascular Center

俄罗斯联邦, Saratov; Saratov

Igor Salov

V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia

Email: salov.i.a@mail.ru
ORCID iD: 0000-0002-1926-5418

Dr. Med. Sci., Professor, Head of Obstetrics and Gynecology Department

俄罗斯联邦, Saratov

Andrey Rebrov

V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia

Email: andreyrebrov@yandex.ru
ORCID iD: 0000-0002-3463-7734

Dr. Med. Sci., Professor, Head of Hospital Therapy Department

俄罗斯联邦, Saratov

参考

  1. Shlyakhto E.V., Zvartau N.E., Villevalde S.V., Yakovlev A.N., Soloveva A.E., Alieva A.S. et al. Cardiovascular risk management system: prerequisites for developing, organization principles, target groups. Russian Journal of Cardiology. 2019; 24(11): 69-82. (in Russian). https://dx.doi.org/10.15829/ 1560-4071-2019-11-69-82.
  2. Юренева С.В., Ильина Л.М., Сметник В.П. Старение репродуктивной системы женщин: от теории к клинической практике. Часть I. Эндокринные и клинические характеристики стадий репродуктивного старения женщин. Акушерство и гинекология. 2014; 3: 21-7. [Yureneva S.V., Ilyina L.M., Smetnik V.P. Female reproductive system aging: From theory to clinical practice. Part 1. The endocrine and clinical characteristics of female reproductive system aging stages. Obstetrics and Gynecology. 2014; (3): 21-7. (in Russian)].
  3. Podzolkov V.I., Bragina A.E., Podzolkovа N.M. Menopausal hormone therapy and heart disease prevention: desired or valid? Cardiovascular Therapy and Prevention. 2019; 18(3): 94-106. (In Russian). https://dx.doi.org/10.15829/1728-8800-2019-3-94-106.
  4. Mumusoglu S., Yildiz B.O. Metabolic syndrome during menopause. Curr. Vasc. Pharmacol. 2019; 17(6): 595-603. https://dx.doi.org/10.2174/ 1570161116666180904094149.
  5. Esedova A.E., Urudzheva N.G., Il’ina I.Yu. Menopausal metabolic syndrome and the risks of menopausal hormone therapy: the solutions. Russian Journal of Woman and Child Health. 2020; 3(4): 260-6. (in Russian). https://dx.doi.org/10.32364/2618-8430-2020-3-4-260-266.
  6. Yureneva S.V., Ilyina L.M. Female reproductive system aging: From theory to clinical practice. Part 2. Role of hormone therapy in solving the problems of transition stage and early postmenopause. Obstetrics and Gynegology. 2014; (4): 17-24. (in Russian).
  7. Baber R.J., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50. https://dx.doi.org/10.3109/ 13697137.2015.1129166.
  8. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017; 24(7): 728-53. https://dx.doi.org/10.1097/GME.0000000000000921.
  9. Yureneva S.V., Ermakova E.I. The management of women with menopausal disorders (review of clinical guidelines). Russian Journal of Human Reproduction. 2017; 23(5):115-22. (in Russian)]. https://dx.doi.org/10.17116/repro2017235115-122.
  10. Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W. et al.; STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19(4): 387-95. https://dx.doi.org/10.1097/gme.0b013e31824d8f40.
  11. Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L. et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020; 41(1): 111-88. https://dx.doi.org/10.1093/eurheartj/ehz455.
  12. Peacock J.L., Peacock P.J. Oxford handbook of medical statistics. Oxford university press; 2011. 517p.
  13. Lin J.W., Caffrey J.L., Chang M.H., Lin Y.S. Sex, menopause, metabolic syndrome, and all-cause and cause-specific mortality--cohort analysis from the Third National Health and Nutrition Examination Survey. J. Clin. Endocrinol. Metab. 2010; 95(9): 4258-67. https://dx.doi.org/10.1210/jc.2010-0332.
  14. Heidari R., Sadeghi M., Talaei M., Rabiei K., Mohammadifard N., Sarrafzadegan N. Metabolic syndrome in menopausal transition: Isfahan Healthy Heart Program, a population based study. Diabetol. Metab. Syndr. 2010; 2: 59. https://dx.doi.org/10.1186/1758-5996-2-59.
  15. Hallajzadeh J., Khoramdad M., Izadi N., Karamzad N., Almasi-Hashiani A., Ayubi E. еt al. Metabolic syndrome and its components in premenopausal and postmenopausal women: a comprehensive systematic review and meta-analysis on observational studies. Menopause. 2018; 25(10): 1155-64. https://dx.doi.org/10.1097/GME.0000000000001136.
  16. Gurka M.J., Vishnu A., Santen R.J., DeBoer M.D. Progression of metabolic syndrome severity during the menopausal transition. J. Am. Heart Assoc. 2016; 5(8): e003609. https://dx.doi.org/10.1161/JAHA.116.003609.
  17. Zhu D., Chung H.F., Dobson A.J., Pandeya N., Anderson D.J., Kuh D. et al. Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies. Am. J. Obstet. Gynecol. 2020; 223(6): 898. e1-898. e16. https://dx.doi.org/10.1016/j.ajog.2020.06.039.
  18. Dam V., Dobson A.J., Onland-Moret N.C., van der Schouw Y.T., Mishra G.D. Vasomotor menopausal symptoms and cardiovascular disease risk in midlife: A longitudinal study. Maturitas. 2020; 133: 32-41. https://dx.doi.org/10.1016/ j.ajog.2020.06.039.
  19. Tolstov S.N., Salov I.A., Rebrov A.P. Relationship between the severity of endothelial dysfunction and metabolic disorders and the severity of climacteric syndrome. Obstetrics and Gynecology. 2021; (8): 119-26. (in Russian). https://dx.doi.org/10.18565/aig.2021.8.119-126.
  20. Tuomikoski P., Savolainen-Peltonen H. Vasomotor symptoms and metabolic syndrome. Maturitas. 2017; 97: 61-5. https://dx.doi.org/10.1016/ j.maturitas.2016.12.010.
  21. Vinogradova Y., Coupland C., Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested casecontrol studies using the QResearch and CPRD databases. BMJ 2015; 350: h2135. https://dx.doi.org/10.1136/bmj.h2135.
  22. FDA Office of Surveillance and Epidemiology. Combined Hormonal Contraceptives (CHCs) and the risk of cardiovascular disease endpoints. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/ UCM277384.pdf
  23. DobrokhotovaYu.E., Borovkova E.I. The personalized approach to choosing a contraceptive: weighing the pros and cons. Gynecology. 2017; 19(3): 40-4 (in Russian). https://dx.doi.org/10.26442/2079-5696_19.3.40-44.
  24. Wu C.Q., Grandi S.M., Filion K.B., Abenhaim H.A., Joseph L., Eisenberg M.J. Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review. BJOG. 2013; 120(7): 801-10. https://dx.doi.org/10.1111/1471-0528.12210.
  25. Bird S.T., Delaney J.A., Etminan M., Brophy J.M., Hartzema A.G. Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol. J. Thromb. Haemost. 2013; 11(6): 1059-68. https://dx.doi.org/10.1111/jth.12224.
  26. Andreeva E.N., Sokolova D.A., Grigoryan O.R. Contraception in obese women. Obesity and metabolism. 2016; 13(3): 65-9 (in Russian)]. https://dx.doi.org/10.14341/OMET2016365-69.
  27. Tolstov S.N., Salov I.A., Rebrov S.N. The severity of abdominal obesity and disorders of carbohydrate metabolism in women in early postmenopausal women and the possibility of correction of the revealed violations. Farmateka. 2017; (3): 36-40. (in Russian).
  28. Prilepskaya V.N., Novikova E.P. Drospirenone-containing contraceptives – options are expanding. Farmateka. 2012; (12): 49-52. (in Russian).

补充文件

附件文件
动作
1. JATS XML
下载
2. Figure. Change in body weight (a) and severity of abdominal obesity (b) against the background of ongoing therapy

下载 (170KB)
索引源数据

版权所有 © Bionika Media, 2023
##common.cookie##